Nuveen
ZNTL icon

Nuveen’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Nuveen’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Buy
+66,674
New +$266K ﹤0.01% 3473
2025
Q2 		– Sell
-507,527
Closed -$807K – 3426
2025
Q1 		$807K Sell
507,527
-133,880
-21% -$289K ﹤0.01% 2734
2024
Q4 		$1.94M Buy
641,407
+167,062
+35% +$547K ﹤0.01% 2401
2024
Q3 		$1.75M Buy
474,345
+344,037
+264% +$1.25M ﹤0.01% 2486
2024
Q2 		$533K Hold
130,308
– – ﹤0.01% 2966
2024
Q1 		$2.05M Hold
130,308
– – ﹤0.01% 2389
2023
Q4 		$1.97M Buy
130,308
+2,138
+2% +$31.2K ﹤0.01% 2415
2023
Q3 		$2.57M Buy
128,170
+10,774
+9% +$273K ﹤0.01% 2195
2023
Q2 		$3.31M Buy
117,396
+2,885
+3% +$69.2K ﹤0.01% 2112
2023
Q1 		$1.97M Sell
114,511
-1,559
-1% -$31.6K ﹤0.01% 2337
2022
Q4 		$2.34M Sell
116,070
-7,496
-6% -$161K ﹤0.01% 2311
2022
Q3 		$2.68M Buy
123,566
+11,239
+10% +$307K ﹤0.01% 2243
2022
Q2 		$3.16M Sell
112,327
-5,995
-5% -$159K ﹤0.01% 2205
2022
Q1 		$5.79M Sell
118,322
-2,334
-2% -$126K ﹤0.01% 1977
2021
Q4 		$8.6M Sell
120,656
-8,383
-6% -$649K ﹤0.01% 1788
2021
Q3 		$9.07M Sell
129,039
-7,560
-6% -$436K ﹤0.01% 1845
2021
Q2 		$7.27M Buy
136,599
+19,699
+17% +$1.06M ﹤0.01% 2058
2021
Q1 		$5.07M Buy
116,900
+10,908
+10% +$470K ﹤0.01% 2166
2020
Q4 		$5.5M Buy
105,992
+65,359
+161% +$2.95M ﹤0.01% 2022
2020
Q3 		$1.33M Buy
40,633
+169
+0.4% +$5.92K ﹤0.01% 2563
2020
Q2 		$1.94M Buy
+40,464
New +$1.55M ﹤0.01% 2350

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nuveen's ZNTL Position: Q2 2026 in Review

Nuveen opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 66,674 shares worth $323K. The stake represents ﹤0.01% of the portfolio and ranks #3473 among its holdings. This is a return to the name: Nuveen previously reported a position in ZNTL as recently as Q1 2025.

Nuveen first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $9.07M in Q3 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Nuveen held 66,674 shares of Zentalis Pharmaceuticals worth $323K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Nuveen position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3473 holding.
  • Nuveen first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Nuveen's Zentalis Pharmaceuticals position peaked at $9.07M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.